Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04445701 · ClinicalTrials.gov registry record · Phase 1

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Arch Oncology.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
6
Study locations

NCT04445701 is a Phase 1 study of Multiple Myeloma that has completed, run by Arch Oncology. The registered enrollment target is 10 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04445701, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Arch Oncology.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
6
Study locations

Study Summary

Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG AO-176
  • DRUG AO-176 + Dex
  • DRUG AO-176 + Dex + Bort

Study Locations (6)

Arizona

  • Mayo Clinic - Phoenix

Florida

  • Mayo Clinic - Jacksonville

Georgia

  • Emory University - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic - Rochester

Wisconsin

  • Medical College of Wisconsin and Froedtert Hospital - Milwaukee

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-11-30
Est. Completion 2022-11-14
Phase Phase 1

Sponsor

Arch Oncology

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04445701

The ClinicalTrials.gov registry entry for NCT04445701 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is Arch Oncology, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which AO-176 is the first listed.

NCT04445701 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT04445701 about?

NCT04445701 is a clinical study titled "Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma". Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).

What is the current status of trial NCT04445701?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-11-30. Estimated completion is 2022-11-14.

What conditions does trial NCT04445701 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT04445701?

The interventions under investigation include: AO-176 (DRUG), AO-176 + Dex (DRUG), AO-176 + Dex + Bort (DRUG).

Who is sponsoring clinical trial NCT04445701?

This trial is sponsored by Arch Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04445701 being conducted?

This trial has 6 study locations across Arizona, Florida, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.